Download Free Cognitive Enhancement In Schizophrenia And Related Disorders Book in PDF and EPUB Free Download. You can read online Cognitive Enhancement In Schizophrenia And Related Disorders and write the review.

A practical guide on how to assess and treat schizophrenia and related disorders using cognitive rehabilitation.
Disturbances of various domains of cognitive function have been shown to provide a major determinant of outcome for patients with psychiatric conditions. Cognitive impairment is present in an array of diseases, including schizophrenia (with its prodromal stage), mood disorder, autism spectrum disorder, obsessive-compulsive disorder, anxiety disorder, post-traumatic disorder, and eating disorder. In an effort to develop effective therapeutics for cognitive impairment, bridging of preclinical and clinical evidence has been attempted. This edited Book will provide a forum for researchers and clinicians interested in the phenomenology, underlying mechanisms, and treatment of cognitive impairment associated with psychiatric illnesses. Twenty-eight contributions from 8 countries in Europe, Middle East, Asia, North America, and South America represent studies dealing with genetic, molecular, imaging, physiological, psychological, and behavioral issues. Information in this Book will facilitate the development of therapeutics of greater clinical value.
Provides state-of-the-art information about cognition in schizophrenia with a wide ranging focus on measuring and treating cognitive deficits.
Social Cognition in Schizophrenia: From Evidence to Treatment provides a firm grounding in the theory and research of normal social cognition, builds on this base to describe how social cognition appears to be dysfunctional in schizophrenia, and explains how this dysfunction might be ameliorated.
Although the precise mechanisms and pathways of schizophrenia remain something of a mystery, there is little dispute that cognitive deficits present as some of the clearest and most debilitating symptoms of the disease. This book describes the characteristics of cognitive deficits in schizophrenia, functional implications, the course of impairments, the genetic and biological contributions and reviews management options, including neuropsychological, psychological and pharmacological techniques. Chapters are written by leading experts in the field, in an accessible and highly informative style, ensuring the content is clinically relevant. State-of-the-art information about new developments in the treatment of related features of the illness, such as disability, is provided. The wide ranging focus of this volume will appeal to clinicians and academic researchers working with patients impaired by severe mental illness.
Cognitive Enhancement: Pharmacologic, Environmental and Genetic Factors addresses the gap that exists in research on the topic, gathering multidisciplinary knowledge and tools that help the reader understand the basics of cognitive enhancement. It also provides assistance in designing procedures and pharmacological approaches to further the use of novel cognitive enhancers, a field that offers potential benefit to a variety of populations, including those with neurologic and psychiatric disorders, mild aging-related cognitive impairment, and those who want to improve intellectual performance. The text builds on our knowledge of the molecular/cellular basis of cognitive function, offering the technological developments that may soon enhance cognition. Separate sections cover enhancement drugs, environmental conditions, and genetic factors in terms of both human and animal studies, including both healthy/young and aging/diseased individuals. Provides a multidisciplinary knowledge, enabling a further understanding of cognitive enhancement Offers coverage of the pharmacologic, environmental, and genetic factors relevant to the topic Discusses cognitive enhancement from the perspective of both healthy and diseased or aging populations Topics are discussed in terms of both human and animal studies
This volume covers the dramatic developments that have occurred in basic neuroscience and clinical research in cognitive neurology and dementia. It is based on the clinical approach to the patient, and provides essential knowledge that is fundamental to clinical practice.
For the first time in a single volume, distinguished experts address the complex issues -- issues rarely confronted in empirical studies of patients with schizophrenia -- and controversial research surrounding the assessment of negative symptoms and cognitive deficits in patients with schizophrenia. Despite recent advances in our understanding of schizophrenia, still notably absent is consensus in assessing negative symptom treatment response. What is the most effective assessment method -- given the varying methodologies and contradictory results to date? What constitutes an adequate response? Which medication -- none is specifically indicated and licensed for negative symptom treatment -- yields the best results? What are the indications for use of this medication? Which instrument best measures negative symptom treatment response (eight rating scales are analyzed here)? Reaching consensus among clinicians and researchers alike is even more difficult because assessment is often thwarted by extrapyramidal side effects of medications, similarities to depressive symptoms, and secondary effects of psychotic experiences. In addition to clarifying these pressing issues, Negative Symptom and Cognitive Deficit Treatment Response in Schizophrenia also discusses The importance of measuring the experience of emotion versus the more traditional objectively measured symptoms in patients with schizophrenia, and how deficits in emotional experience may resist treatment -- even in treatment-responsive patients. The family as an often overlooked source of information about negative symptom improvement or worsening, and the impact of negative symptoms on patients' relatives. How treatment affects social functioning and subjective experience of "quality of life," and the importance of neurocognitive dysfunction in the social deficits of schizophrenia, which often persist despite significant amelioration of other symptoms. Specific guidelines for assessing neurocognitive treatment response. Cognitive enhancement is a major factor in improving the quality of patients' lives. The latest research on the neurobiology of negative symptoms, including the role of various neurotransmitter systems and brain regions in mediating negative symptom pathology. Also discussed is single vs. multiple pathophysiological processes and single treatment modality vs. distinct treatments for different aspects of negative symptoms. How to distinguish "pure" negative symptoms from deficit symptoms (i.e., those that persist for at least 1 year and are not secondary to factors such as depression, medication side effects, anxiety, delusions, and hallucinations), and which treatment is indicated for each. Highlighted by patient vignettes, this in-depth guide will be welcomed by all clinicians who treat patients with schizophrenia and want to know and document whether their interventions ameliorate negative symptoms and cognitive dysfunction, and by all researchers who study schizophrenia, particularly those interested in clinical issues and treatment studies.
Research shows that neuro- and social cognition have a decisive influence on functional outcome in people with schizophrenia. In this publication, world-renowned experts summarize the latest research on approaches to assessing and treating cognition in schizophrenia. The book is organized to take the reader through the steps from definitions and assessment of cognition to research on the relevance of cognition in everyday life, to chapters which focus on treatments for cognitive disorders. The reader will learn about the NIMH MATRICS initiative which has provided clinicians and researchers with the tools to define and assess neuro- and social cognitive functioning in people with schizophrenia. Then the treatments for neuro and social cognitive deficits are discussed in several chapters which give an overview of cognitive remediation approaches, accompanied by concrete treatment examples. The reader will also learn about the latest results of pharmacological interventions for cognitive deficits. A final chapter focuses on the importance of addressing motivational deficits when treating cognition, and offers treatment approaches to enhance motivation. This publication is essential reading for clinicians and researchers in the fields of psychiatry, psychology as well as students and other professions working with people who have schizophrenia.
Could CRT provide the first structured method of alleviating cognitive deficits associated with schizophrenia? Cognitive Remediation Therapy for Schizophrenia describes the background and development of this new psychological therapy and demonstrates how it provides the first structured help to overcome the thinking problems associated with schizophrenia. In three sections, the book covers the theoretical and empirical underpinning of cognitive remediation therapy and explores its application. Part I, 'The Development of Therapy', provides the historical context and theoretical background to the therapy and emphasizes the value of rehabilitating cognitive deficits. In Part II, 'Improving Cognitive Processes', the process and effects of changing cognition are examined. Finally, in Part III, 'The Process of Therapy', the authors provide a clinical guide to the delivery of cognitive remediation therapy and use case examples to support its efficacy. This book is the first to describe an individual cognitive remediation therapy programme based on a clear model of the relationship between thinking and behaviour. It will be of both academic and clinical value to all those health professionals and clinical academics who want not only to understand the relationships between thought and action but also to intervene to improve therapy.